Study of Drug Resistance in Ovarian Cancer Cells
Author Information
Author(s): Erba E, Bergamaschi D, Bassano L, Ronzoni S, Liberti G Di, Muradore I, Vignati S, Faircloth G, Jimeno J, D'Incalci M
Primary Institution: Cancer Pharmacology Laboratory, Department of Oncology, Istituto di Ricerche Farmacologiche ‘Mario Negri’
Hypothesis
Can exposure to Ecteinascidin-743 (ET-743) create drug-resistant ovarian cancer cell lines?
Conclusion
The study found that the Igrov-1/25 ET cell line became highly resistant to ET-743 and exhibited increased levels of Pgp without gene amplification.
Supporting Evidence
- The most resistant clone, Igrov-1/25 ET, showed an IC50 value approximately 50 times higher than the parental cell line.
- Resistance was maintained even after 24 months in drug-free conditions.
- Igrov-1/25 ET was cross-resistant to Doxorubicin and VP16 but sensitive to other drugs.
- The cyclosporine analogue SDZ PSC-833 reversed the resistance to ET-743.
Takeaway
Researchers made ovarian cancer cells resistant to a drug by exposing them to it for a long time, and they found that these cells could push the drug out more effectively.
Methodology
The study involved exposing Igrov-1 human ovarian cancer cells to increasing concentrations of ET-743 to create resistant sublines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website